Renovaro Inc. (RENB) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended March 31, 2025 (Q3 Fiscal 2025) for Renovaro Inc. (formerly Renovaro Biosciences Inc.). The company operates through two primary segments: Renovaro Biosciences (developing allogeneic cell and gene therapies for cancer and infectious diseases) and Renovaro Cube (an AI-driven healthcare technology platform for early cancer detection). The company is a pre-revenue, pre-clinical entity focused on shifting resources toward the commercialization of its AI diagnostics platform.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income (Loss) | $189,176 | $(58,990,070) | $(51,275,253) | $(72,694,219) |
| Operating Expenses | $4,162,492 | $51,380,840 | $62,047,361 | $64,535,029 |
| Cash and Equivalents | $923,002 | $312,697 | $923,002 | $312,697 |
| Working Capital | $(25,173,586) | $(28,312,274) | $(25,173,586) | $(28,312,274) |
| Total Assets | $117,726,120 | $163,129,450 | $117,726,120 | $163,129,450 |
| Total Liabilities | $29,339,269 | $31,152,306 | $29,339,269 | $31,152,306 |
Material Changes vs. Prior Period
- Net Income Turnaround: The company reported a net income of $189,176 for Q3 2025, a significant improvement from a net loss of $58.99 million in Q3 2024. This shift was primarily driven by a $11.6 million gain from the change in fair value of contingent consideration and the absence of the $42.6 million intangible asset impairment recorded in the prior year.
- Goodwill Impairment: For the nine months ended March 31, 2025, the company recorded a goodwill impairment of $47.6 million related to the Renovaro Cube reporting unit, driven by a decline in estimated fair value due to capital raising challenges. This offset some of the expense reductions.
- Expense Reduction: Operating expenses decreased by 92% in Q3 2025 compared to Q3 2024, largely due to the elimination of prior-year impairments and reduced general and administrative costs (down 45%).
- Liquidity Improvement: Cash balances increased from $220,467 at the end of the prior fiscal year (June 30, 2024) to $923,002 as of March 31, 2025, supported by financing activities including private placements and notes payable.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern for one year following the report date. The company has an accumulated deficit of $383.7 million and a working capital deficit of $25.2 million. Continued operations depend on securing additional equity or debt financing.
- Equity Offering: As of March 31, 2025, the company had received $3.0 million in proceeds from an equity offering but had not yet closed. These funds are classified as a liability ("Stock subscription payable") because investors retain the right to a refund if the offering does not close.
- Legal Proceedings:
- Securities Class Action: A settlement stipulation was signed in November 2024 regarding the "Chow Action." Preliminary approval is pending court consideration.
- Derivative Litigation: Multiple shareholder derivative actions (Koenig, Solak, Midler) remain stayed pending the resolution of the class action settlement.
- Company Lawsuit: The company is pursuing a lawsuit against former partners (G Tech, SRI, Wittekind) alleging fraud and falsification of study results, seeking approximately $25 million in damages. Trial is reset for November 2026.
- Subsequent Event: On April 8, 2025, the company consummated the acquisition of Biosymetrics, Inc., issuing 15.0 million shares of common stock.
Investor Verification Checklist
- Financing Status: Verify the closing status of the $15 million equity offering and the classification of the $3 million currently held as a liability.
- Goodwill Valuation: Review the assumptions used for the $47.6 million goodwill impairment and the current fair value of the Renovaro Cube reporting unit.
- Legal Settlements: Monitor the final court approval of the securities class action settlement and the potential financial impact.
- Related Party Debt: Examine the terms and maturity dates of the $5.7 million in notes payable to related parties (Paseco ApS, RS Bio, etc.).
- Internal Controls: Note the material weakness in internal controls over financial reporting due to a lack of resources for complex accounting matters.